Monomethyl Fumarate
Unusual Cancers of Childhood
OHSU Knight Cancer InstituteSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Unusual Cancers of Childhood cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Anti-Thymoglobulin, Rabbit OHSU Knight Cancer Institute | Phase 2 | CCC |
TACROLIMUS OHSU Knight Cancer Institute | Phase 2 | CCC |
CARMUSTINE OHSU Knight Cancer Institute | Phase 2 | CCC |
Evomela OHSU Knight Cancer Institute | Phase 2 | CCC |
CYCLOSPORIN A OHSU Knight Cancer Institute | Phase 2 | CCC |
Fludarabine OHSU Knight Cancer Institute | Phase 2 | CCC |
Same molecule, other indications
Monomethyl Fumarate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →